Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Bruno de La Rochebrochard
  • Bruno de La Rochebrochard

ELIOR (SELL, TP EUR4.7) | Q1 revenue less impacted than expected but F...

ELIOR (SELL, TP EUR4.7) | Q1 revenue less impacted than expected but FY guidance suspended

Bruno de La Rochebrochard
  • Bruno de La Rochebrochard

SGS SA (BUY, TP CHF3400) | Sustained FY results slightly ahead expecta...

SGS SA (BUY, TP CHF3400) | Sustained FY results slightly ahead expectation

Dylan Van Haaften
  • Dylan Van Haaften

GALAPAGOS (SELL, TP EUR71) | Habemus CEO! Dr. Paul Stoffels joins GLPG

GALAPAGOS (SELL, TP EUR71) | Habemus CEO! Dr. Paul Stoffels joins GLPG

Dylan Van Haaften
  • Dylan Van Haaften

XVIVO PERFUSION - BUY | SEK440(+106%) 4Q caps a year of volatility, bu...

XVIVO PERFUSION - BUY | SEK440(+106%) 4Q caps a year of volatility, but is better than feared New revenue streams in ’22 should augur well for growth … … but no clear guidance on ’22 organic growth We re-iterate our BUY and SEK 440 TP on XVIVO

Gregory Ramirez
  • Gregory Ramirez

SOFTWARE AG: Reassuring results and guidance | BUY | EUR52(+75%)

SOFTWARE AG - BUY | EUR52(+75%) Reassuring results and guidance We reiterate our Buy rating FY21 results exceed expectations at the operating margin level The move to subscriptions and SaaS advances well FY22 guidance shows solid progress and FY23 targets are reiterated

Victor Floc’h
  • Victor Floc’h

ONCODESIGN (CORPORATE, TP EUR15) | R&D collaboration signed with TiumB...

ONCODESIGN (CORPORATE, TP EUR15) | R&D collaboration signed with TiumBio in fibrosis

Victor Floc’h
  • Victor Floc’h

GENEURO (BUY, TP EUR6) | First patient completed the ProTEct-MS study ...

GENEURO (BUY, TP EUR6) | First patient completed the ProTEct-MS study and entered the extension part

Eric Lemarie
  • Eric Lemarie

LEGRAND: Inflation might start to pinch – downgraded and removed from ...

LEGRAND - NEUTRAL vs. BUY TOP PICKS | EUR90(+2%) Inflation might start to pinch – downgraded and removed from Top Picks (company contact) Tension in the supply chain… …combined with an acceleration in inflation… …is clouding visibility on H2 as pricing power has limits A more cautious stance on the share price. Removed from Top Picks.

Thomas Coudry
  • Thomas Coudry

VIVENDI: Football rights: new kick off | BUY | EUR27 VS. EUR26

VIVENDI - BUY | EUR27 VS. EUR26 (+5%) Football rights: new kick off Following the failure of Mediapro, the door is wide open for Canal+ Getting a return on additional spend will be challenging… … but value lies elsewhere Removed from top pick list, Buy confirmed.

Olga Smolentseva
  • Olga Smolentseva

4D PHARMA (CORPORATE, TP 407p) | Presentations at SITC support MRx0518...

4D PHARMA (CORPORATE, TP 407p) | Presentations at SITC support MRx0518 development:

ResearchPool Subscriptions

Get the most out of your insights

Get in touch